Acetazolamide Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Acetazolamide Supply in 2026

Acetazolamide (Diamox) remains a cornerstone medication for conditions ranging from glaucoma to idiopathic intracranial hypertension (IIH) and altitude sickness prevention. While it's not currently listed on the FDA or ASHP drug shortage lists, providers should be aware of intermittent availability challenges that continue to affect patient access — particularly for the injectable and extended-release formulations.

This briefing covers the current supply landscape, prescribing implications, cost considerations, and tools to help your patients access Acetazolamide reliably.

Supply Timeline and Current Status

Acetazolamide has a history of supply fluctuations, primarily affecting its injectable formulation:

• Oral tablets (125 mg, 250 mg): Currently available from multiple generic manufacturers including Teva Pharmaceuticals, Zydus Lifesciences, and Accord Healthcare. Supply has been generally stable for the oral immediate-release formulation.
• Extended-release capsules (500 mg): The Diamox Sequels brand was discontinued, and generic extended-release 500 mg capsules are produced by a limited number of manufacturers. Availability can be inconsistent at the pharmacy level.
• Injectable (500 mg powder for reconstitution): This formulation has experienced the most significant supply disruptions over the past several years. X-Gen Pharmaceuticals has been one of the few producers, and production issues have led to periodic shortages affecting hospital and emergency department use.

As of early 2026, no formulation of Acetazolamide appears on the FDA Drug Shortage Database or ASHP Current Shortages list. However, localized availability gaps persist, and some patients report difficulty filling prescriptions through retail pharmacies.

Prescribing Implications

Understanding the supply landscape can inform prescribing decisions:

Formulation Selection

When clinically appropriate, prescribing the immediate-release 250 mg tablet maximizes the likelihood that your patient can fill the prescription. This formulation has the broadest manufacturer base and most consistent availability. If a patient requires the extended-release formulation (e.g., for compliance reasons), consider including a note on the prescription allowing the pharmacist to substitute the immediate-release equivalent if the ER is unavailable.

Indication-Specific Considerations

• Glaucoma: If systemic therapy with Acetazolamide is not filling reliably, consider topical carbonic anhydrase inhibitors (Dorzolamide, Brinzolamide) as first-line alternatives. Methazolamide remains available as an oral alternative with potentially better tolerability.
• Idiopathic intracranial hypertension: Acetazolamide remains the standard of care for IIH. If unavailable, Topiramate (which has weak carbonic anhydrase inhibitory properties) has been used off-label, though evidence is more limited. Furosemide has also been used in combination therapy.
• Altitude sickness: No oral alternative has equivalent evidence. Dexamethasone is an alternative for prevention and treatment but carries a different risk profile. Advise patients to obtain prescriptions well in advance of travel.
• Epilepsy: Acetazolamide is typically an adjunctive therapy. If unavailable, optimize the primary anticonvulsant and consider Zonisamide, which has carbonic anhydrase inhibitory activity, as a potential substitute.

Duration and Quantity

For patients with chronic conditions (glaucoma, IIH), prescribing 90-day supplies when feasible can reduce the frequency of pharmacy visits and decrease the risk of running out during temporary supply disruptions. Many insurance plans and mail-order pharmacies support 90-day fills at a reduced per-unit cost.

Current Availability Picture

The following summarizes the availability of Acetazolamide formulations in early 2026:

• Acetazolamide 125 mg tablet: Widely available at retail pharmacies
• Acetazolamide 250 mg tablet: Widely available at retail pharmacies
• Acetazolamide ER 500 mg capsule: Available but may require checking multiple pharmacies or using mail-order
• Acetazolamide 500 mg injection: Intermittently available; hospital procurement teams should maintain contacts with multiple distributors

For real-time pharmacy stock checks, Medfinder for Providers enables clinicians to verify which pharmacies near a patient's location have Acetazolamide in stock before sending the prescription.

Cost and Access Considerations

Acetazolamide's status as an established generic keeps costs manageable for most patients:

• Cash price: Approximately $134 for 60 tablets of 250 mg at retail
• With discount coupons: $14 to $20 for the same quantity (GoodRx, SingleCare)
• Insurance: Typically covered on Tier 1 or Tier 2 (preferred generic); copays generally $0-$15
• Prior authorization: Rarely required for generic Acetazolamide; may be needed for higher quantities or ER formulation on some plans

For uninsured or underinsured patients, no manufacturer patient assistance program exists (as there is no active brand). However, prescription discount programs and state pharmaceutical assistance programs may help. Direct patients to resources like NeedyMeds.org and RxAssist.org for additional options.

Tools and Resources for Your Practice

• Medfinder for Providers — Real-time pharmacy stock search. Verify Acetazolamide availability near your patient before prescribing.
• ASHP Drug Shortages — Monitor the official shortage list at ashp.org for any changes in Acetazolamide supply status.
• FDA Drug Shortage Database — Additional tracking at FDA.gov for manufacturer-reported supply disruptions.
• GoodRx / SingleCare — Recommend these free coupon services to uninsured patients to reduce out-of-pocket costs by up to 90%.

Looking Ahead

The generic Acetazolamide market has remained relatively stable for oral formulations, and there are no signals of impending major shortages as of early 2026. However, the injectable formulation remains vulnerable due to its limited manufacturer base. Providers working in settings that depend on IV Acetazolamide should maintain contingency plans and consider therapeutic alternatives when appropriate.

For additional clinical context, see our companion articles on helping patients find Acetazolamide in stock and helping patients save money on Acetazolamide.

Final Thoughts

Acetazolamide remains a widely available and affordable generic medication for most patients. Awareness of formulation-specific supply challenges and proactive prescribing strategies can minimize disruptions in patient care. Leveraging tools like Medfinder for Providers adds an extra layer of assurance that your patients can fill their prescriptions without unnecessary delays.